<DOC>
	<DOCNO>NCT00230815</DOCNO>
	<brief_summary>This prospective , open-label , multicenter , trial evaluate subject satisfaction efficacy follitropin alfa injection apply Pen device compare subject 's previous experience injectable gonadotropin oligoanovulatory infertile woman undergo ovulation induction</brief_summary>
	<brief_title>A Phase 3b Study Evaluate Subject Satisfaction With Follitropin Alfa Injection Oligoanovulatory Infertile Women Undergoing Ovulation Induction</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Infertile woman wish conceive least 1 previous cycle treatment injectable gonadotropin within past 6 month , exclude treatment gonadotropin multidose formulation vial administer Pen device , whose physician recommend undergo ovulation induction . This inclusion criterion modify include subject previous treatment gonadotropin multidose formulation vial , exclude gonadotropin administer Pen device Premenopausal age 1840 year , inclusive Ovulatory dysfunction define follow ( ) usual cycle length le ( &lt; ) 21 great ( &gt; ) 35 day least 6 menses per year ( b ) usual cycle length &gt; 35 day less 6 menses per year . Subjects group must positive response progesterone challenge within past 6 month screen period Spontaneous menses positive response progestin withdrawal within 6 month start gonadotropin therapy positive response clomiphene citrate withdrawal least 30 day prior start gonadotropin therapy acceptable demonstrate induced menses Normal Papanicolaou ( PAP ) smear within 6 month prior initial visit Male partner acceptable semen analysis within 6 month prior study entry , accord standard practice clinic , ovulation induction . Use donor sperm acceptable Body mass index ( BMI ) less 35.0 kilogram per square meter ( kg/m^2 ) . BMI = Body Weight / Height x Height ( BMI equal body weight [ kilogram { kg } ] divide Height * Height [ square meter { m^2 } ] ) Patency apparent normality least 1 fallopian tube ipsilateral functional ovary , document hysterosonogram hysterosalpingography ( HSG ) within 3 year prior study entry Local laboratory screen result demonstrate follow , within past year : ( ) prolactin within normal limit ( b ) Follicle stimulate hormone ( FSH ) within normal limit early follicular phase local laboratory ( c ) thyroid stimulate hormone ( TSH ) within normal limit . Subjects low TSH level receive replacement therapy could enrol discretion Investigator Been willing able comply protocol duration study Voluntarily provide write informed consent subject authorization Health Insurance Portability Accountability Act ( HIPAA ) , prior studyrelated procedure part normal medical care , understanding consent could withdraw subject time without prejudice future medical care . The male partner must also provide write subject authorization HIPAA Clinically significant systemic disease clinically significant abnormal hematology , chemistry , urinalysis result screen Previous treatment gonadotropin multidose formulation vial administer Pen device past 6 month Any significant allergic disease , opinion Investigator could interfere study treatment Known infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B C virus Prior severe Ovarian Hyperstimulation Syndrome ( OHSS ) Significant allergic response gonadotropin preparation Ongoing pregnancy , pregnancy within 3 month prior study entry , contraindication pregnancy carry pregnancy term Clinically significant abnormal finding evident transvaginal pelvic ultrasound perform within 2 cycle ( maximum 90 day ) study entry Poor response prior gonadotropin stimulation cycle , define estradiol level &lt; 100 pg/mL per mature follicle ( &gt; =16 mm mean diameter ) Prior excessive response gonadotropin stimulation define development &gt; 3 mature follicle treatment dose 75 IU FSH Treatment gonadotropin , clomiphene citrate , insulinsensitizing agent ( e.g. , metformin , Avandia® ) Gonadotropin Releasing Hormone ( GnRH ) analog within 1 month prior study entry Hypothyroidism ( untreated ) . Subjects low Thyroid Stimulating Hormone ( TSH ) level receive replacement therapy ( e.g. , Synthroid ) could enrol discretion Investigator local laboratory result demonstrate satisfactory thyroid function Hyperprolactinemia ( untreated ) Abnormal , undiagnosed , gynecological bleed Known current American Society Reproductive Medicine ( ASRM ) Stage 3 4 endometriosis A residual ovarian cyst mean diameter &gt; 25 mm estradiol ( E2 ) &gt; 100 pg/mL baseline examination Three consecutive pregnancy loss , due cause Known current substance abuse ( include smoker consume 5 cigarettes/day ) Previous participation ( within 3 month prior study entry ) another investigational drug drug delivery system trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Oligoanovulatory infertility</keyword>
	<keyword>Follitropin alfa</keyword>
	<keyword>Pen device</keyword>
	<keyword>Gonal-f®</keyword>
	<keyword>Recombinant Human Choriogonadotropin ( r-hCG )</keyword>
	<keyword>Ovidrel®</keyword>
</DOC>